Treatment Clinical Trials for Prostate Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for prostate cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 101-125 of 318
< Previous 1 2 3 4 5 6 7 ... 13 Next >

  • Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

    The purpose of this trial is to investigate the safety and tolerability of TAS3681, to find the maximum tolerated dose (MTD) / recommended dose of TAS3681 (Escalation Phase) and to further evaluate safety and preliminary efficacy of TAS3681 at the MTD / recommended dose (Expansion Phase).
    Location: 4 locations

  • Carbohydrate-Restricted Diet in Treating Patients with Previously Treated Prostate Cancer

    This randomized phase II trial studies how well carbohydrate-restricted diet works in treating patients with previously treated prostate cancer. A low-carbohydrate diet may prevent or slow disease progression in patients with prostate cancer who failed to respond to prior therapy.
    Location: 4 locations

  • Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

    This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.
    Location: 5 locations

  • PK and Dose Escalation and Expansion Study of DST-2970

    This is a Phase I multi-center, open-label, study of DST-2970 to determine the MTD, overall safety / tolerability, PK / pharmacodynamic parameters, and efficacy in prostate cancer patients.The study will include a dose escalation phase followed by a dose expansion phase. Each cohort will consist of a "run-in" period to assess pharmacokinetic trough, as well as C1hour, C2hour, and C3hour levels of standard of care abiraterone acetate, followed by a minimum of an 80-hour washout (treatment delay), then initiation of treatment with DST-2970. The patient population that will be evaluated in this study include patients with castration sensitive or castration resistant prostate cancer who experience a rising PSA, with or without radiographic progression, while taking abiraterone acetate. In this protocol, "initial PSA response to abiraterone" is defined as having a ≥ 30% drop in PSA levels (confirmed by a second PSA level one month later) during the first 6 months of treatment with abiraterone. These patients who subsequently experience a rise in PSA while on abiraterone are considered as having "acquired resistance" to abiraterone in the context of this protocol. Patients not meeting the definition of having an "initial PSA response to abiraterone" are considered as having "primary resistance" to abiraterone in the context of the protocol. In the dose escalation phase, all patients with a rising PSA can be enrolled, whether they had an "initial PSA response to abiraterone" or never responded to abiraterone. Two expansion cohorts will be opened. One expansion cohort will evaluate patients who did achieve an "initial PSA response to abiraterone" within the first 6 months of treatment as defined above, but subsequently progressed by PSA with or without radiographic progression. A second expansion cohort will evaluate patients who did not achieve an "initial PSA response to abiraterone" as defined above but have PSA progression with or without radiographic progression. The rationale of the study is to determine if the better bioavailability of DST-2970 will overcome resistance to abiraterone acetate experienced in these two clinical settings. In all cohorts, treatment will continue until progressive disease, unacceptable toxicity, investigator and / or sponsor decision, intercurrent illness or patient withdrawal of consent. Patients will be monitored regularly with physical examination and laboratory tests.
    Location: 3 locations

  • Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

    This phase II trial compares high-dose rate brachytherapy and stereotactic ablative radiotherapy as monotherapy in treating patients with prostate cancer that has not spread to other parts of the body (localized). High-dose rate brachytherapy delivers radiation directly into the prostate within a few minutes by a single radioactive seed through temporarily placed plastic catheters inside the prostate gland. Stereotactic ablative radiotherapy is an external beam radiation method that delivers large doses of radiation to the cancer in a short period of time, usually 5 treatments. This trial aims to find which of these two approaches is better in terms of patient-reported quality of life.
    Location: 3 locations

  • Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients

    A Phase 1 / 2 open label trial of intravenous administration of TAEK-VAC-HerBy vaccine in patients with advanced HER2- expressing cancer. The study will be completed in 3 stages. In Stage 1 patients will be enrolled and treated according to a 3+3 dose escalation scheme. Up to 4 dose levels will be explored. Stage 2 will enroll patients with HER2- positive breast and gastric cancer to administer the TAEK-VAC-HerBy vaccine in combination with HER2 antibodies. Stage 3 will enroll patients to evaluate the safety and tolerability of the TAEK-VAC-HerBy vaccine in combination with HER2 antibodies and PD-1 / PD-L1 antibody. Patients, in all three stages, will receive TAEK-VAC-HerBy every three weeks, three administrations in total.
    Location: 5 locations

  • An Extension Study MRI / US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue

    To determine the efficacy of using MRI / US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation.
    Location: 4 locations

  • Conventional or Hypofractionated Radiation Therapy in Treating Patients with Prostate Cancer

    This phase III trial studies how well hypofractionated radiation therapy works compared to the conventional one in treating patients with prostate cancer. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
    Location: 3 locations

  • Enzalutamide with or without Radium Ra 223 Dichloride in Patients with Metastatic, Castration-Resistant Prostate Cancer

    This randomized phase II trial studies how well enzalutamide with or without radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to other places in the body. Enzalutamide is an androgen receptor inhibitor that may slow down the growth of prostate cancer by blocking the action of the male hormone testosterone and other male hormones called androgens. Radiation therapy uses high energy alpha particles to kill tumor cells and shrink tumors. Enzalutamide with or without radium Ra 223 dichloride may work better in treating patients with castration-resistant prostate cancer.
    Location: 3 locations

  • 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

    The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.
    Location: 3 locations

  • First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors

    This study is a Phase 1, first-in-human, open-label, dose-escalation study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of IMGC936 administered by intravenous (IV) infusion.
    Location: 3 locations

  • A Study of FT-7051 in Men With MCRPC

    This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer who have progressed despite prior therapy and had been treated with at least one potent anti-androgen therapy. The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days on / 7 days off) in 28-day cycles.
    Location: 4 locations

  • Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

    This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone / prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone / prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone / prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone / prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and / or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.
    Location: 5 locations

  • Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.
    Location: 3 locations

  • P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.
    Location: 4 locations

  • First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

    CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. In part I, patients will receive ascending dosages of CCW702 with the goal to determine the maximum tolerated dose (MTD) of CCW702. In part II of the study, patients will be given the recommended phase 2 dose (RP2D) evaluating two regimens of CCW702 to determine which regimen is most efficacious. The study will also assess the pharmacokinetics and pharmacodynamics of CCW702.
    Location: 3 locations

  • A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

    This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.
    Location: 4 locations

  • Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

    The primary objectives of the study in Dose Escalation are to evaluate safety, tolerability, and pharmacokinetics (PK) of REGN5678 alone and in combination with cemiplimab and in Dose Expansion are to assess efficacy, as measured by objective response rate (ORR) per modified Prostate Cancer Working Group 3 (PCWG3) criteria, of REGN5678 in combination with cemiplimab. The secondary objectives of the study in Dose Escalation are to assess efficacy, as measured by ORR per modified PCWG3 criteria, of REGN5678 in combination with cemiplimab and in Dose Expansion are to characterize the safety profile in each expansion cohort and to characterize the PK of REGN5678 in combination with cemiplimab. Secondary objectives in both Dose Escalation and Dose Expansion are to assess efficacy of REGN5678 in combination with cemiplimab, as measured by additional criteria and to assess immunogenicity of REGN5678 in combination with cemiplimab.
    Location: 5 locations

  • A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

    The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
    Location: 3 locations

  • Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

    This study is designed to evaluate multiple clinical hypotheses and mechanistically-defined combinations to evaluate the safety and efficacy of immunotherapy combinations in participants with mCRPC who have received prior secondary androgen receptor signaling inhibitor therapy (eg, abiraterone, enzalutamide, apalutamide).
    Location: 4 locations

  • Nivolumab and Degarelix with or without BMS-986253 in Treating Patients with Hormone-Sensitive Prostate Cancer

    This phase Ib / II trial studies the side effects and how well nivolumab and degarelix with or without BMS-986253 work in treating patients with prostate cancer that is sensitive to hormone therapy. Immunotherapy with monoclonal antibodies, such as nivolumab and BMS-986253, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Testosterone can cause the growth of prostate cancer cells. Drugs, such as degarelix, may lessen the amount of testosterone made by the body. It is not yet known whether giving nivolumab and degarelix with or without BMS-986253 will work better in treating patients with hormone-sensitive prostate cancer.
    Location: 4 locations

  • Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

    The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.
    Location: 3 locations

  • Pembrolizumab in Treating Patients with Metastatic Castration Resistant Prostate Cancer with or without DNA Damage Repair Defects

    This phase II trial studies how well pembrolizumab works in treating patients with castration resistant prostate cancer with or without deoxyribonucleic acid (DNA) damage repair defects that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 3 locations

  • Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

    The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.
    Location: 3 locations

  • Hypofractionated Radiation Therapy for the Treatment of Prostate Cancer

    This trial compares how well extended hypofractionated radiation therapy and accelerated hypofractionated radiation therapy works in treating patients with prostate cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Shortening the course of treatment may improve the convenience and decrease the burden of cancer treatment for patients and their families.
    Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida


< Previous 1 2 3 4 5 6 7 ... 13 Next >